Tech Company Financing Transactions
Sigilon Therapeutics Funding Round
Sigilon Therapeutics, based in Cambridge, secured $23.5 million from Flagship Pioneering.
Transaction Overview
Company Name
Announced On
6/22/2017
Transaction Type
Venture Equity
Amount
$23,500,000
Round
Undisclosed
Investors
Flagship Pioneering (Douglas Cole)
Proceeds Purpose
The company will develop products that emerge from its discovery platform to treat serious hematologic, enzyme deficiency and endocrine disorders.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 Binney St. 600
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Sigilon Therapeutics (Nasdaq: SGTX) was founded and created by Flagship Pioneering. Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials, developed at the Massachusetts Institute of Technology (MIT), that can shield implanted cells from immune attack.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rogerio Vivaldi
Chief Financial Officer
Glenn Reicin
Chief Medical Officer
Deya Corzo
Chief Technical Officer
David Peritt
Vice President
Hozefa Bandukwala
Vice President
Olivia Kelly
VP - Bus. Development
Anne Altmeyer
VP - Engineering
Susan Drapeau
VP - Finance
Josias Pontes
VP - General Counsel
Melodie Henderson
VP - General Counsel
Matthew Kowalsky
VP - Human Resources
Vanya Sagar
VP - Manufacturing
Martha Rook
VP - Operations
Devyn Smith
Browse more venture capital transactions:
Prev: 6/22/2017: Rinse venture capital transaction
Next: 6/22/2017: Adaptive Insights venture capital transaction
Share this article
About Database of VC Transactions
We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs